# COBALT-RCC (NCT04438083)

> A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)

No report yet. It can be ordered.

- Drugs tested: CTX130
- Indication: advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04438083
- Phase: PHASE1
- Status: TERMINATED
- Sponsor: CRISPR Therapeutics AG
- Conditions: Renal Cell Carcinoma
- Interventions: CTX130
- Enrollment: 19
- Primary outcome: Part A (dose escalation): Incidence of adverse events
- Primary outcome: Part B (cohort expansion): Objective response rate

## Indexed commentary on COBALT-RCC so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 11 posts on X
- 2 YouTube videos

## Order

Standard, $1,250 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=cobalt-rcc-nct04438083

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04438083", "email": "<work email>"}; the inbox owner confirms by the emailed link.